Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CUE

Cue Biopharma, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CUE. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Cue Biopharma, Inc. (NASDAQ: CUE) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 13:09 UTC.

What Cue Biopharma, Inc. does

The company is a clinical-stage biopharmaceutical firm developing injectable therapeutics using its Immuno-STAT platform to selectively engage and modify disease-specific T cells for treating autoimmune, inflammatory, and oncology diseases. The platform includes three series: the CUE-400 series designed to promote regulatory T cells and restore immune balance in autoimmune conditions, the CUE-500 series intended to redirect anti-viral T cells to eliminate pathogenic cells, and the CUE-100 series aimed at activating tumor-specific T cells for oncology applications.

Summarized from Cue Biopharma, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-100.64%

Revenue, margins & earnings

FY2021: net loss $44M on revenue $15M$15MFY2021FY2022: net loss $53M on revenue $1M$1MFY2022FY2023: net loss $51M on revenue $5M$5MFY2023FY2024: net loss $41M on revenue $9M$9MFY2024FY2025: net loss $27M on revenue $27M$27MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-14
  • 2026-10-14Chief Legal Compliance OfficerSale-1,844$51.7K
  • 2026-10-14Chief Executive OfficerSale-1,087$30.5K
  • 2026-10-14Chief Executive OfficerSale-10,000$275.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Cue Biopharma, Inc. do?

The company is a clinical-stage biopharmaceutical firm developing injectable therapeutics using its Immuno-STAT platform to selectively engage and modify disease-specific T cells for treating autoimmune, inflammatory, and oncology diseases.

When did CUE last file with the SEC?

Cue Biopharma, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-10. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 13:09 UTC. This page is also available as JSON at /api/data?ticker=CUE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CUE and 5,000+ tickers.

Create a free account — keep CUE
For your agent
GET /api/data?ticker=CUE

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt